(NewsDirect)
PrescientTherapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updatesProactive’s Elisha Newell after the biotech showcased pre-clinicalCellPryme and OmniCAR data at the International Society of Cell andGene Therapy (ISCT)’s annual meeting. The team briefed an expertcell therapy audience on two abstracts in a move Yatomi-Clarkebelieves exemplifies the Prescient pipeline’s utility andinnovation. The CEO says there’s plenty of news to come in FY24 asPrescient readies CellPryme and OmniCAR for clinicalstudies.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.